TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17604885

Group type: EXPERIMENTAL
Intervention: 1% lidocaine with epinephrine
Number of subjects: 96

Group type: COMPARATOR
Intervention: 1% lidocaine
Number of subjects: 96
Study: 17089219

Group type: EXPERIMENTAL
Intervention: Thermal mineral water treatment
Number of subjects: 64

Group type: COMPARATOR
Intervention: Tap water treatment
Number of subjects: 64
Study: 16429619

Group type: EXPERIMENTAL
Intervention: 3 mg SL Apomorphine (APO)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 11304865

Group type: EXPERIMENTAL
Intervention: ThinPrep DFA
Number of subjects: 636

Group type: COMPARATOR
Intervention: Conventional DFA
Number of subjects: 636

Group type: EXPERIMENTAL
Intervention: Specimen adequacy
Number of subjects: 636

Group type: COMPARATOR
Intervention: Chlamydia prevalence
Number of subjects: 636
Study: 10998469

Group type: EXPERIMENTAL
Intervention: 400 mg bezafibrate once daily
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (age‐ and sex‐matched subjects)
Number of subjects: 16
Study: 8831156

Group type: EXPERIMENTAL
Intervention: Nodding head while encoding positive and negative adjectives
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shaking head while encoding positive and negative adjectives
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Head movements compatible with words during encoding
Number of subjects: 0

Group type: COMPARATOR
Intervention: Head movements incompatible with words during encoding
Number of subjects: 0
Study: 1596721

Group type: EXPERIMENTAL
Intervention: Nissen total transabdominal fundoplication (360 degrees wrap)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Lind partial transabdominal fundoplication (300 degrees wrap)
Number of subjects: 52
Study: 6697730

Group type: EXPERIMENTAL
Intervention: Continuous transcutaneous oxygen (PtcO2) monitoring during the open TcM period
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control period (PtcO2 data withheld)
Number of subjects: 20
Study: 30820940

Group type: EXPERIMENTAL
Intervention: Pentostatin, cyclophosphamide, and rituximab (PCR)
Number of subjects: 83
Study: 28328729

Group type: EXPERIMENTAL
Intervention: Two-thumb technique (TTT)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Two-finger technique (TFT-R23)
Number of subjects: 37
Study: 27102319

Group type: EXPERIMENTAL
Intervention: Toothpaste with 250 ppm F
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Toothpaste with 500 ppm F
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Toothpaste with 1250 ppm F
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: No rinsing after brushing
Number of subjects: 32

Group type: COMPARATOR
Intervention: Rinsing after brushing
Number of subjects: 32
Study: 24655345

Group type: EXPERIMENTAL
Intervention: PECS training
Number of subjects: 14

Group type: COMPARATOR
Intervention: Conventional language therapy (CLT)
Number of subjects: 14
Study: 22441361

Group type: EXPERIMENTAL
Intervention: S(+)‐ketamine infusion for 60 hours
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 66
Study: 20100272

Group type: EXPERIMENTAL
Intervention: Calcium hydroxylapatite (CaHA) premixed with 2% lidocaine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Calcium hydroxylapatite (CaHA) alone
Number of subjects: 50
Study: 18076580

Group type: EXPERIMENTAL
Intervention: Ledermix
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcium hydroxide
Number of subjects: 0

Group type: COMPARATOR
Intervention: No medication
Number of subjects: 0
Study: 15572276

Group type: EXPERIMENTAL
Intervention: Risperidone (4.2±1.7 mg/day)
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Haloperidol (8.0±3.6 mg/day)
Number of subjects: 438

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Risperidone and Haloperidol (4.1±1.8 mg/day and 7.4±3.7 mg/day respectively) during the subsequent 9 weeks
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 438
Study: 12540319

Group type: EXPERIMENTAL
Intervention: Nortriptyline (Pamelor) with weekly behavioral therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bupropion
Number of subjects: 0
Study: 9703790

Group type: EXPERIMENTAL
Intervention: Sodium selenite in combination with physical therapy for 3 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 7600143

Group type: EXPERIMENTAL
Intervention: Ebrotidine 800 mg
Number of subjects: 298

Group type: COMPARATOR
Intervention: Ranitidine 300 mg
Number of subjects: 298
Study: 2192562

Group type: EXPERIMENTAL
Intervention: Intensive group psychotherapy plus imipramine or placebo
Number of subjects: 68

Group type: COMPARATOR
Intervention: Imipramine maintenance
Number of subjects: 68

Group type: COMPARATOR
Intervention: Attendance at maintenance group sessions
Number of subjects: 68
Study: 30779530

Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression (median of 22 hours daily for a median of 7 days)
Number of subjects: 2003

Group type: COMPARATOR
Intervention: Pharmacologic thromboprophylaxis alone (control group)
Number of subjects: 2003

Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression
Number of subjects: 2003
Study: 28877512

Group type: EXPERIMENTAL
Intervention: Oxytocin (OXT)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 26181910

Group type: EXPERIMENTAL
Intervention: High-intensity rehabilitation programme with cognitive behavioural therapy
Number of subjects: 54

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 54
Study: 23642951

Group type: EXPERIMENTAL
Intervention: True Individualised Western Herbal Medicine (IWHM) tinctures
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo Individualised Western Herbal Medicine (IWHM) tinctures
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo IWHM
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: True IWHM
Number of subjects: 0
Study: 21286495

Group type: EXPERIMENTAL
Intervention: Alcohol (vodka tonic targeting 0.05g% concentration) at 0400 with high homeostatic load (12.25 hrs awake)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Alcohol (vodka tonic targeting 0.05g% concentration) at 1600 with medium homeostatic load (8.25 hrs awake)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Alcohol (vodka tonic targeting 0.05g% concentration) at 1000 with medium homeostatic load (6.25 hrs awake)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Alcohol (vodka tonic targeting 0.05g% concentration) at 2200 with high homeostatic load (10.25 hrs awake)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo at various times of day
Number of subjects: 26
Study: 19187523

Group type: EXPERIMENTAL
Intervention: HSV suppressive therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repeated post-randomisation measurements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pre-randomisation measurements of plasma HIV-1 RNA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repeated post-randomisation measurements of plasma HIV-1 RNA
Number of subjects: 0
Study: 16898386

Group type: COMPARATOR
Intervention: TTT
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: TTT+
Number of subjects: 21
Study: 15069846

Group type: EXPERIMENTAL
Intervention: Interactive multimedia learning tool
Number of subjects: 0

Group type: COMPARATOR
Intervention: Text only, text and images, multimedia learning explanations
Number of subjects: 0
Study: 11315821

Group type: EXPERIMENTAL
Intervention: Insulin glargine (HOE 901) once daily (n = 259)
Number of subjects: 518

Group type: COMPARATOR
Intervention: NPH insulin once or twice daily (n = 259)
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: Insulin glargine (HOE 901) once daily
Number of subjects: 518

Group type: COMPARATOR
Intervention: NPH insulin once or twice daily
Number of subjects: 518
Study: 9220540

Group type: EXPERIMENTAL
Intervention: IA-2 beta
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: IA-2
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: GAD65
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Combination of IA-2 beta and IA-2
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Combination of IA-2 beta and GAD65
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Combination of IA-2 and GAD65
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Blocking with recombinant IA-2, IA-2 beta, or GAD65
Number of subjects: 76
Study: 8189572

Group type: EXPERIMENTAL
Intervention: Laparoscopic pelvic lymph node dissection followed by radical perineal prostatectomy (group 1)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Laparoscopic pelvic lymph node dissection and radical retropubic prostatectomy (group 2)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Standard open lymphadenectomy and radical retropubic prostatectomy (group 3)
Number of subjects: 76
Study: 3400843

Group type: EXPERIMENTAL
Intervention: Intranasal cocaine alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intranasal cocaine with adrenaline 1:1000
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study: 31383449

Group type: EXPERIMENTAL
Intervention: Anapanasati meditation (daily for 6 months)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 90
Study: 28373411

Group type: EXPERIMENTAL
Intervention: Intense interval training (IIT, n=8)
Number of subjects: 15

Group type: COMPARATOR
Intervention: No exercise control (n=7)
Number of subjects: 15
Study: 26226227

Group type: EXPERIMENTAL
Intervention: Insulin (2-mg bovine insulin/kg body mass)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Oleate (OL) (300 μg/kg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Octanoate (OCT) (300 μg/kg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Insulin + Oleate
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Insulin + Octanoate
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (saline solution alone)
Number of subjects: 15
Study: 24471325

Group type: EXPERIMENTAL
Intervention: New allergic skin test instrument group
Number of subjects: 300

Group type: COMPARATOR
Intervention: Normal allergic skin test instrument group
Number of subjects: 300

Group type: COMPARATOR
Intervention: Traditional skin test group
Number of subjects: 300
Study: 21807930

Group type: EXPERIMENTAL
Intervention: HMB/ARG/LYS (n = 40)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control (isonitrogenous, n = 37)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: HMB/ARG/LYS (n = 40) with vitamin D status <30 ng 25OH-vitD(3)/mL
Number of subjects: 77
Study: 18507269

Group type: EXPERIMENTAL
Intervention: Community‐based care (CBC)
Number of subjects: 307

Group type: COMPARATOR
Intervention: Enhanced usual care (EUC)
Number of subjects: 307
Study: 17135039

Group type: EXPERIMENTAL
Intervention: Cyclical hormone replacement therapy (HRT) with conjugated equine estrogens (CEE) plus medroxyprogesterone acetate (MPA) for 1 year
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 17beta-estradiol gel with the same schedule of MPA administration for 1 year
Number of subjects: 9
Study: 14561977

Group type: EXPERIMENTAL
Intervention: Linezolid
Number of subjects: 22
Study: 11116776

Group type: EXPERIMENTAL
Intervention: Emotionally charged story (arousing story)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Neutral story
Number of subjects: 44
Study: 9219145

Group type: EXPERIMENTAL
Intervention: Methamphetamine abuse
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Drug use before or during sex
Number of subjects: 16
Study: 1451715

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 6198057

Group type: EXPERIMENTAL
Intervention: Prioderm lotion (0.5% malathion in isopropanol)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Kwellada shampoo (1% lindane)
Number of subjects: 62
Study: 29133220

Group type: EXPERIMENTAL
Intervention: Exercise + Diet
Number of subjects: 149

Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 149

Group type: COMPARATOR
Intervention: Diet
Number of subjects: 149

Group type: COMPARATOR
Intervention: Control
Number of subjects: 149
Study: 26843538

Group type: EXPERIMENTAL
Intervention: Initial physiotherapist examination and follow-up clinical evaluation
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Follow-up clinical evaluation after 7 days
Number of subjects: 90

Group type: COMPARATOR
Intervention: MRI evaluation
Number of subjects: 90
Study: 25668306

Group type: EXPERIMENTAL
Intervention: Bazedoxifene 20 mg
Number of subjects: 1530

Group type: EXPERIMENTAL
Intervention: Bazedoxifene 40 mg
Number of subjects: 1530

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1530

Group type: EXPERIMENTAL
Intervention: Bazedoxifene
Number of subjects: 1530
Study: 23792399

Group type: EXPERIMENTAL
Intervention: Single-visit root canal treatment
Number of subjects: 287

Group type: COMPARATOR
Intervention: Two-visit root canal treatment
Number of subjects: 287
Study: 20862744

Group type: EXPERIMENTAL
Intervention: Mucinous adenocarcinoma
Number of subjects: 4000

Group type: COMPARATOR
Intervention: Serous carcinoma
Number of subjects: 4000
Study: 18368947

Group type: EXPERIMENTAL
Intervention: Procaterol (20 µg, inhaled three times a day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Oxitropium bromide (200 µg, inhaled three times a day)
Number of subjects: 20
Study: 17165499

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with Chinese medicine
Number of subjects: 58

Group type: COMPARATOR
Intervention: Chinese medicine
Number of subjects: 58
Study: 15375474

Group type: EXPERIMENTAL
Intervention: Open commissurotomy (GC)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Balloon valvuloplasty (GV)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Both groups (GC and GV)
Number of subjects: 81
Study: 11100349

Group type: EXPERIMENTAL
Intervention: Cyclic total parenteral nutrition (TPN) when total bilirubin > 5 mg% (Group A2)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Cyclic total parenteral nutrition (TPN) when total bilirubin > 10 mg% (Group B2)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Cyclic total parenteral nutrition (TPN) when total bilirubin > 20 mg% (Group C2)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Non-cyclic total parenteral nutrition (TPN)
Number of subjects: 65
Study: 9745829

Group type: EXPERIMENTAL
Intervention: Belgian OAG patients
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Congolese OAG patients
Number of subjects: 51

Group type: COMPARATOR
Intervention: Belgian normal eyes
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Congolese specimens
Number of subjects: 51

Group type: COMPARATOR
Intervention: Belgian specimens
Number of subjects: 51
Study: 8383933

Group type: EXPERIMENTAL
Intervention: Doxacurium (0.05 mg/kg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pancuronium (0.14 mg/kg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pipecuronium (0.10 mg/kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Pancuronium, Pipecuronium, Doxacurium
Number of subjects: 30
Study: 3724575

Group type: EXPERIMENTAL
Intervention: Interprofessional training programme in ambulatory diabetes care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Teaching role assigned to nurses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Learning from a nurse
Number of subjects: 0
Study: 31615775

Group type: EXPERIMENTAL
Intervention: 10 mg of testosterone cream daily for 10 weeks
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo for 10 weeks
Number of subjects: 48
Study: 28984843

Group type: EXPERIMENTAL
Intervention: Weekly family psychosocial intervention
Number of subjects: 391

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 391
Study: 26690886

Group type: EXPERIMENTAL
Intervention: BCAA supplementation
Number of subjects: 256

Group type: COMPARATOR
Intervention: Sorafenib without BCAA supplementation
Number of subjects: 256
Study: 25402400

Group type: EXPERIMENTAL
Intervention: Community Engagement Planning (CEP)
Number of subjects: 1018

Group type: COMPARATOR
Intervention: Technical Assistance to Individual Programs (RS)
Number of subjects: 1018
Study: 22648466

Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg · kg‐1)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 20921123

Group type: EXPERIMENTAL
Intervention: Acamprosate (initial oral loading followed by 1998 mg daily)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 33
Study: 19419923

Group type: EXPERIMENTAL
Intervention: Bevacizumab combined with carboplatin/paclitaxel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bevacizumab combined with cisplatin/gemcitabine
Number of subjects: 0
Study: 15976996

Group type: EXPERIMENTAL
Intervention: Maximal inspiratory pressure (MIP) post-exercise
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Handgrip (HG) strength post-exercise
Number of subjects: 34
Study: 11406895

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 11
Study: 9372653

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (975 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ozone (0.12 ppm)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ozone (0.4 ppm)
Number of subjects: 0
Study: 8447444

Group type: EXPERIMENTAL
Intervention: AVP
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: dDAVP
Number of subjects: 6
Study: 3501540

Group type: EXPERIMENTAL
Intervention: FUra plus leucovorin (200 mg/m2 daily for 5 days)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: FUra plus leucovorin (20 mg/m2 daily for 5 days)
Number of subjects: 78

Group type: COMPARATOR
Intervention: FUra (control)
Number of subjects: 78
Study: 30365408

Group type: EXPERIMENTAL
Intervention: 2.5% topical ketoprofen gel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29720874

Group type: EXPERIMENTAL
Intervention: Life coaching intervention
Number of subjects: 14
Study: 28116440

Group type: EXPERIMENTAL
Intervention: PBL combined with SP
Number of subjects: 104

Group type: COMPARATOR
Intervention: LBL
Number of subjects: 104
Study: 22981277

Group type: EXPERIMENTAL
Intervention: Adenosine myocardial perfusion imaging (MPI) with heart rate response (HRR) measurement
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: HRR <20%
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: Moderate/large abnormal MPI
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: HRR ≥ 40%
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: Both abnormal MPI and HRR
Number of subjects: 518
Study: 21562038

Group type: EXPERIMENTAL
Intervention: Intravenous methotrexate (IV MTX) during interim maintenance phases
Number of subjects: 2078

Group type: COMPARATOR
Intervention: Oral methotrexate (PO MTX) during interim maintenance phases
Number of subjects: 2078

Group type: EXPERIMENTAL
Intervention: Single delayed intensification (DI) phase
Number of subjects: 2078

Group type: COMPARATOR
Intervention: Double delayed intensification (DI) phase
Number of subjects: 2078
Study: 19433681

Group type: EXPERIMENTAL
Intervention: Modified high-dose induction phase (arm A): 4 weeks of 10 MU/m² IFN-alpha-2b IV for 2 weeks and 10 MU/m² IFN-alpha-2b SC for 2 weeks followed by 23 months of low-dose IFN-alpha-2b 3 MU SC three times a week
Number of subjects: 674

Group type: COMPARATOR
Intervention: Low-dose IFN-alpha-2b only (arm B): 3 MU three times a week for 24 months
Number of subjects: 674
Study: 16857846

Group type: EXPERIMENTAL
Intervention: 200 microg of Se per day
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 400 microg of Se per day
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 12603782

Group type: EXPERIMENTAL
Intervention: Tryptophan-free amino acid drink (TFD)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control drink (TFD plus tryptophan)
Number of subjects: 5
Study: 10990220

Group type: EXPERIMENTAL
Intervention: Folic acid (5 mg tablet once daily for 13 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Methotrexate (MTX) alone (10 mm/week)
Number of subjects: 20
Study: 9266782

Group type: EXPERIMENTAL
Intervention: Epoprostenol infusion
Number of subjects: 471

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 471
Study: 8336195

Group type: EXPERIMENTAL
Intervention: Cisplatin and mitomycin (CM)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Cisplatin and doxorubicin (CD)
Number of subjects: 70
Study: 3297596

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Adenosine triphosphate (ATP)
Number of subjects: 57
Study: 29065734

Group type: EXPERIMENTAL
Intervention: 22G FNA needle
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 22G FNB needle
Number of subjects: 60
Study: 27596004

Group type: EXPERIMENTAL
Intervention: Nurse-led telephone counseling (n = 24)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (n = 30)
Number of subjects: 54
Study: 25649237

Group type: EXPERIMENTAL
Intervention: Computerized malnutrition-screening system with dietetic referral
Number of subjects: 1457

Group type: EXPERIMENTAL
Intervention: Computerized malnutrition-screening system
Number of subjects: 1457

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1457
Study: 23643690

Group type: EXPERIMENTAL
Intervention: GDT performed 5min after stress onset
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: GDT performed 18min after stress onset
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: GDT performed 28min after stress onset
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control group GDT performance
Number of subjects: 3
Study: 20883237

Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study: 18383415

Group type: EXPERIMENTAL
Intervention: Infliximab plus methotrexate (MTX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22111436

Group type: EXPERIMENTAL
Intervention: Laryngeal Tube Suction II (LTS II)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Proseal Laryngeal Mask Airway (PLMA)
Number of subjects: 54
Study: 16148284

Group type: EXPERIMENTAL
Intervention: Levofloxacin (500 mg once daily for seven days)
Number of subjects: 1565

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1565
Study: 11792952

Group type: EXPERIMENTAL
Intervention: Octylcyanoacrylate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Suture
Number of subjects: 0